Cellegy Pharmaceuticals, Inc., has initiated a second Phase III clinical trial to provide confirmatory evidence that Anogesic (nitroglycerin ointment) reduces the average daily pain associated with anal fissures. Initiation of this trial follows review by the US FDA of the study protocol and the results of a recently completed Phase III trial. In the recently Read more about Cellegy Begins Phase III Clinical Trial With Anogesic[…]